An overall 22％ yield synthesis of a MET kinase inhibitor LY2801653 was achieved over eight steps, starting with 3-hydroxybenzaldehyde.Highlights of the process chemistry design and development include: a Cu-catalyzed cyclization to selectively form an N 1-methylindazole ring, a selective nitro reduction in the presence of an aryl bromide, a late stage Suzuki cross-coupling, and a base promoted Boc-deprotection to form the desired drug candidate.